Do DIO2 rs225014 (Thr92Ala) and DIO1 rs2235544 variants impair T4-to-T3 conversion?

The conversion of inactive thyroxine (T4) to the biologically active triiodothyronine (T3) relies on deiodinase enzymes. Genetic variations in the DIO1 and Address DIO2 genes can impair this critical metabolic pathway.

Clinical and genetic evidence

Clinical association studies demonstrate that the DIO2 rs225014 (Thr92Ala) and DIO1 rs2235544 polymorphisms are significantly associated with altered thyroid hormone levels.

• Altered thyroid ratios: Carriers of the DIO2 Ala/Ala genotype and the DIO1 rs2235544 A allele exhibit lower serum T3 levels and a reduced free T3 to free T4 (FT3/FT4) ratio.
• Impact on therapy: This effect is particularly pronounced in patients on levothyroxine (T4) monotherapy (such as post-thyroidectomy patients), where peripheral conversion by deiodinases is the sole source of circulating T3.

Mechanistic pathways

These genetic variants directly alter deiodinase enzyme efficiency and local tissue feedback:

• Enzymatic conversion efficiency: The DIO2 Thr92Ala substitution results in a lower-activity type 2 deiodinase (D2) isoform, while the DIO1 rs2235544 variant alters type 1 deiodinase (D1) activity, directly impairing the catalytic conversion of T4 to active T3.
• Pituitary feedback: This impaired deiodinase activity also occurs locally in the pituitary gland, reducing T4-to-T3 conversion and altering TSH feedback dynamics due to decreased pituitary sensitivity to circulating thyroid hormones.

Metabolic and systemic implications

Reduced tissue-specific T3 generation impacts broader metabolic outcomes:

• Insulin resistance: Impaired intracellular T3 generation in peripheral metabolic tissues, linked specifically to the low-activity DIO2 Thr92Ala variant, is associated with increased insulin resistance and poorer glycemic control (higher HbA1c) in patients with type 2 diabetes.

Bottom line

• The DIO2 rs225014 (Thr92Ala) and DIO1 rs2235544 genetic variants are associated with impaired peripheral T4-to-T3 conversion and a lower FT3/FT4 ratio, which can alter pituitary feedback mechanisms and exacerbate insulin resistance and glycemic dysfunction.